Wenxin (Vincent) Xu, MD

Final Thoughts/Looking Forward

July 29th 2024

The Role of Chemotherapy in nccRCC Treatment

July 29th 2024

Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

July 29th 2024

World Health Organization (WHO) Classification Updates for Papillary RCC

July 29th 2024

Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

July 29th 2024

Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

July 29th 2024

Dr Voss Application of Updated KEYNOTE-564 Data

July 16th 2024

Martin Voss, MD, elaborates on the impact of the KEYNOTE-564 trial and its recently presented data on the management of renal cell carcinoma, highlighting how these findings have influenced treatment decisions and patient care strategies.

Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes

July 16th 2024

Wenxin (Vincent) Xu, MD, presents the findings from the phase 3 CONTACT-03 trial, which compared the efficacy of atezolizumab in combination with cabozantinib versus cabozantinib alone in patients with inoperable advanced renal cell carcinoma who had previously received immune checkpoint inhibitor treatment.

Ongoing RCC Clinical Trials that may Impact Practice

July 8th 2024

Pedro Barata, MD, MSc, prompts the panel to share their opinions on which of the discussed clinical trials they find most promising and likely to influence clinical practice in the treatment of renal cell carcinoma.

Exciting Data and Trials in Progress from ASCO 2024

July 8th 2024

Elizabeth Wulff-Burchfield, MD, facilitates a conversation about several clinical trials, such as STELLAR-001 and KEYNOTE-426, which investigate various treatment approaches for renal cell carcinoma (RCC).

Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

July 2nd 2024

Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).

Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

July 2nd 2024

Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC).

Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

June 25th 2024

The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.

Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

June 25th 2024

Dr. Pedro Barata, MD, MSc, provides an overview of advanced clear cell renal cell carcinoma (RCC), discussing its typical presentation, the role of systemic therapies, and summarizing the first-line treatment options available for this condition.

Dr Xu on Ongoing Biomarker Research in Metastatic RCC

April 5th 2024

Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.

Dr Xu on Ongoing Research Initiatives in ccRCC

March 27th 2024

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Dr Xu on Treatment Decision-Making in RCC

March 22nd 2024

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.